Buprenorphine/Naloxone
Treatment for Opioid Use Disorders
Typical Dosage: 8-24 mg/day of buprenorphine equivalent
Effectiveness
85%
Safety Score
58%
Clinical Trials
115
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
8-24 mg/day of buprenorphine equivalent
Time to Effect
Immediate (after induction)
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,400
Monitoring:$3,600
Side Effect Mgmt:$100
Total Annual:$6,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$55,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$9,384.62
Cost per Remission
$15,250
Comparison vs No treatment
Cost Difference
+$6,100/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Buprenorphine/Naloxone Outcomes
for Opioid Use Disorders
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+65%
Remission Rate
+40%
Common Side Effects
Headache
+30%
Nausea
+15%
Constipation
+20%
Sweating
+10%
Drowsiness
+10%
Active Clinical Trials
6 active trials recruiting for Buprenorphine/Naloxone in Opioid Use Disorders
Low-dose Buprenorphine Initiation for Opioid Use Disorder
NCT05450718RECRUITINGPHASE4
70 participants
INTERVENTIONAL
The Bronx, United States
Started: Nov 11, 2024
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments
NCT04893525RECRUITINGPHASE2, PHASE3
658 participants
INTERVENTIONAL
Calgary, Canada +5 more
Started: Jul 23, 2021
Low-dose Versus a High-dose Sublingual Buprenorphine Induction
NCT05944952ACTIVE NOT RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Dundalk, United States
Started: Jun 20, 2024
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
NCT05011266RECRUITINGPHASE2, PHASE3
180 participants
INTERVENTIONAL
Rockville, United States +1 more
Started: Apr 18, 2023
A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
NCT06726200RECRUITINGEARLY_PHASE1
60 participants
INTERVENTIONAL
New York, United States
Started: Nov 1, 2025
Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
NCT04234191RECRUITINGPHASE2
50 participants
INTERVENTIONAL
Vancouver, Canada
Started: Aug 18, 2021
Completed Clinical Trials
6 completed trials for Buprenorphine/Naloxone in Opioid Use Disorders
Buprenorphine Loading in the Emergency Department
NCT04283500COMPLETEDPHASE4
15 participants
INTERVENTIONAL
New York, United States
Started: Nov 1, 2020
CBT4CBT for Office Based Buprenorphine
NCT03580902COMPLETEDPHASE1, PHASE2
51 participants
INTERVENTIONAL
New Haven, United States
Started: Jan 22, 2019
Rapid Initiation of Drug Treatment Engagement
NCT03908437COMPLETEDPHASE4
104 participants
INTERVENTIONAL
Philadelphia, United States
Started: Jul 15, 2019
Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075
NCT03248947COMPLETEDEARLY_PHASE1
71 participants
INTERVENTIONAL
Durham, United States +5 more
Started: Mar 28, 2018
A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse
NCT03033732COMPLETEDPHASE4
272 participants
INTERVENTIONAL
Calgary, Canada +6 more
Started: Oct 2, 2017
Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
NCT02044094COMPLETEDPHASE2
39 participants
INTERVENTIONAL
Overland Park, United States
Started: Nov 1, 2013
Showing 20 of 115 total trials